Bacterial Extracellular Vesicles (BEVs) Derived From Lactococcus lactis as Multimodal Drug Delivery Platforms.

IF 3.5 Q3 MATERIALS SCIENCE, BIOMATERIALS
International Journal of Biomaterials Pub Date : 2025-12-31 eCollection Date: 2025-01-01 DOI:10.1155/ijbm/3141223
Sushmita Das, Subrata Das, Subhadeep Gupta, Afruja Khan, Pradip Kumar Tarafdar, Amirul Islam Mallick
{"title":"Bacterial Extracellular Vesicles (BEVs) Derived From <i>Lactococcus lactis</i> as Multimodal Drug Delivery Platforms.","authors":"Sushmita Das, Subrata Das, Subhadeep Gupta, Afruja Khan, Pradip Kumar Tarafdar, Amirul Islam Mallick","doi":"10.1155/ijbm/3141223","DOIUrl":null,"url":null,"abstract":"<p><p>Advances in drug delivery technologies involve the extracellular vesicles as a promising bioactive drug delivery vehicle expected to improve targeted therapeutic delivery in pharmaceutical innovations. Recently, Gram-negative bacterial extracellular vesicles (outer membrane vesicles or OMVs) have gained attention for their role in host-microbe interactions and potential in drug delivery. Bacterial extracellular vesicle (BEV) shedding is a conserved mechanism of intra- and interspecies communication, providing critical insights into host-microbe interactions. However, the biogenesis and compositional diversity of BEVs produced by Gram-positive bacteria remain underexplored. Understanding the translational application potential of BEVs remains elusive due to the suboptimal isolation of BEVs and limited structural-functional characterization. A comprehensive study to develop BEVs as delivery vehicles will provide critical insights into the perspective of microbial-host interplay and illuminate the modulation of the drug delivery strategy. Here, using a food-grade probiotic <i>Lactococcus lacti</i>s subsp. <i>cremoris</i> MG1363 (strain NZ9000), we demonstrated that perturbing peptidoglycan biosynthesis with ampicillin, which targets penicillin-binding proteins (PBPs), significantly enhances BEV production. We further explored the interaction between BEVs and host cells through this optimized BEV biogenesis, revealing its cargo-delivering capability. Furthermore, to understand the potential of BEVs as a multimodal drug delivery platform, we target multidrug-resistant microbial pathogens and cancer cell proliferation with drug-encapsulated BEVs. With a generally recognized as safe (GRAS) recognition of <i>L. lactis,</i> we demonstrated that drug-loaded <i>L. lactis</i> BEVs can offer recognizable therapeutic effects. These findings highlight the versatile nature of <i>L. lactis</i> BEVs as stable, safe, natural nanocarriers capable of personalized cargo delivery with broad therapeutic applications.</p>","PeriodicalId":13704,"journal":{"name":"International Journal of Biomaterials","volume":"2025 ","pages":"3141223"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12755118/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biomaterials","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/ijbm/3141223","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Advances in drug delivery technologies involve the extracellular vesicles as a promising bioactive drug delivery vehicle expected to improve targeted therapeutic delivery in pharmaceutical innovations. Recently, Gram-negative bacterial extracellular vesicles (outer membrane vesicles or OMVs) have gained attention for their role in host-microbe interactions and potential in drug delivery. Bacterial extracellular vesicle (BEV) shedding is a conserved mechanism of intra- and interspecies communication, providing critical insights into host-microbe interactions. However, the biogenesis and compositional diversity of BEVs produced by Gram-positive bacteria remain underexplored. Understanding the translational application potential of BEVs remains elusive due to the suboptimal isolation of BEVs and limited structural-functional characterization. A comprehensive study to develop BEVs as delivery vehicles will provide critical insights into the perspective of microbial-host interplay and illuminate the modulation of the drug delivery strategy. Here, using a food-grade probiotic Lactococcus lactis subsp. cremoris MG1363 (strain NZ9000), we demonstrated that perturbing peptidoglycan biosynthesis with ampicillin, which targets penicillin-binding proteins (PBPs), significantly enhances BEV production. We further explored the interaction between BEVs and host cells through this optimized BEV biogenesis, revealing its cargo-delivering capability. Furthermore, to understand the potential of BEVs as a multimodal drug delivery platform, we target multidrug-resistant microbial pathogens and cancer cell proliferation with drug-encapsulated BEVs. With a generally recognized as safe (GRAS) recognition of L. lactis, we demonstrated that drug-loaded L. lactis BEVs can offer recognizable therapeutic effects. These findings highlight the versatile nature of L. lactis BEVs as stable, safe, natural nanocarriers capable of personalized cargo delivery with broad therapeutic applications.

乳球菌衍生的细菌细胞外囊泡(BEVs)作为多模式给药平台。
细胞外囊泡作为一种很有前途的生物活性药物传递载体,有望改善药物创新中的靶向治疗递送。最近,革兰氏阴性细菌胞外囊泡(外膜囊泡或omv)因其在宿主-微生物相互作用和药物传递中的作用而受到关注。细菌胞外囊泡(BEV)脱落是种内和种间交流的一种保守机制,为宿主-微生物相互作用提供了重要的见解。然而,革兰氏阳性菌产生的bev的生物成因和组成多样性仍未得到充分研究。由于bev的分离不理想和结构功能表征有限,了解bev的转化应用潜力仍然难以捉摸。一项开发bev作为递送工具的综合研究将为微生物-宿主相互作用的角度提供关键见解,并阐明药物递送策略的调节。在这里,使用一种食品级益生菌乳酸乳球菌亚种。研究人员发现,通过干扰氨苄西林的肽聚糖生物合成,可以显著提高BEV的产量。氨苄西林靶向青霉素结合蛋白(PBPs)。通过优化后的BEV生物生成,我们进一步探索了BEV与宿主细胞之间的相互作用,揭示了其载货能力。此外,为了了解bev作为多模式药物传递平台的潜力,我们用药物封装的bev靶向多药耐药微生物病原体和癌细胞增殖。由于乳酸菌具有公认的安全(GRAS)识别,我们证明了载药乳酸菌bev可以提供可识别的治疗效果。这些发现突出了乳酸菌bev作为稳定、安全、天然的纳米载体的多功能性,能够个性化地运送货物,具有广泛的治疗应用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Biomaterials
International Journal of Biomaterials MATERIALS SCIENCE, BIOMATERIALS-
CiteScore
4.30
自引率
3.20%
发文量
50
审稿时长
21 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书